ALEC Alector Inc.

19.76
+0.37  (+2%)
Previous Close 19.39
Open 20.01
Price To Book 6.23
Market Cap 1,361,932,905
Shares 68,923,730
Volume 447,044
Short Ratio
Av. Daily Volume 310,920
Stock charts supplied by TradingView

NewsSee all news

  1. Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

    - Today's AL002 presentation showcases the first data in humans with a TREM2 antibody - AL002 was generally safe and well-tolerated in healthy volunteers - Reduced CSF sTREM2 level demonstrates target engagement -

  2. Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration

  3. Alector to Host R&D Day on December 13, 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will host an R&D Day for

  4. Alector to Present at the Jefferies 2019 London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business

  5. Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results

    Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a C9orf72 mutation (FTD-C9orf72)Initiated AL003 Phase 1b clinical study in genetically

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial initiation announced September 9, 2019.
AL001
Frontotemporal Dementia
Phase 1 data presented at CTAD December 6, 2019 - generally safe and well-tolerated.
AL002
Alzheimer’s disease
Phase 1 trial initiation announced April 3, 2019.
AL003
Alzheimer’s disease

Latest News

  1. Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

    - Today's AL002 presentation showcases the first data in humans with a TREM2 antibody - AL002 was generally safe and well-tolerated in healthy volunteers - Reduced CSF sTREM2 level demonstrates target engagement -

  2. Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration

  3. Alector to Host R&D Day on December 13, 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will host an R&D Day for

  4. Alector to Present at the Jefferies 2019 London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business

  5. Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results

    Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a C9orf72 mutation (FTD-C9orf72)Initiated AL003 Phase 1b clinical study in genetically

  6. Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia

    SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and